Hyperion Defi Inc (HYPD) Stock Price, Quote & News

Company Profile

Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in Chin...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 289 1117

Website: hyperiondefi.com

Address:

295 Madison Avenue, Suite 2400, New York, United States

Vikingsstrade Oct. 4 at 6:02 PM

$FORM $HYPD $MGM $LU Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

Jwa68 Oct. 4 at 2:32 PM

$HYPD Management is often everything when it comes to the ultimate success of any public company. It's always a bet on the jockey. Hyperion Defi has now added two exceedingly talented execs wirh Hyunsu Jung and now David Knox. Both have their goals completely alligned with shareholders. I always say character counts. If you go to LinkedIn and see David Knox's recent activity, you will see something very insightful. Not only did his post announcing his joining the company yield nearly 500 likes, but he personally took a moment to respond to virtually every person who congratulated him. This is highly telling and insightful. He is well respected by those who know him, and he values relationships. He fundamentally understands the importance of goodwill and gratitude. In a public company, goodwill with shareholders and the street in general is foundational to value creation. David clearly doesnt just understand this, but he clearly practices it routinely. Do your DD...

0 · Reply

SpencerF Oct. 3 at 7:52 PM

$HYPD think we just missed the last chance to dump? Or still Possibility of one more rally ahead?

0 · Reply

Vikingsstrade Oct. 3 at 4:29 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $YDES $CIFR $TBN $HYPD

0 · Reply

LoneBroker Oct. 3 at 8:26 AM

$HYPD • $11.83 🐻 • RSI 37.6 • ATR 14.48% • vol↑ Support & Resistance — UPDATED 10/02/2025 5 Days | Support: $9.25 – $9.46 | Resistance: $11.03 – $11.60 20 Days | Support: $8.79 – $9.53 | Resistance: $12.42 – $13.61 60 Days | Support: $5.57 – $6.00 | Resistance: $10.53 – $12.80 HYPD remains under bearish pressure with RSI subdued. ATR of 14.48% highlights ongoing swings, while vol↑ shows how participation is shaping moves. The market tone suggests sellers are guarding resistance areas and buyers are cautious at supports. 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 4:00 PM ET / 1:00 PM PT (Mon–Fri)

0 · Reply

SpencerF Oct. 2 at 10:56 PM

$HYPD good to dump here? Have to do double bottom still?

0 · Reply

SmartBetting Oct. 2 at 8:04 PM

$HYPD i said. goodluck.

0 · Reply

StardustNdreams Oct. 2 at 7:09 PM

$HYPD excellent so far today

0 · Reply

S2K_TP Oct. 2 at 4:38 PM

$HYPD swing idea. Pt: 20+ 🚨🎢

0 · Reply

Drewcifer99 Oct. 2 at 1:33 PM

$HYPD hope the coin goes nuts soon. Would love to see this at $20 to $30!

0 · Reply

Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

Sep 27, 2025, 7:30 AM EDT - 7 days ago

Many crypto-treasury companies are trading for less than what their digital assets are worth. Is this a bargain or a big red flag?

ALTS MARA MSTR

Sep 25, 2025, 8:00 AM EDT - 9 days ago

Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings

Sep 16, 2025, 8:00 AM EDT - 18 days ago

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Aug 14, 2025, 10:16 AM EDT - 7 weeks ago

Kinetiq Announces iHYPE Launch with Hyperion DeFi as First Institutional Depositor

Aug 13, 2025, 4:01 PM EDT - 7 weeks ago

Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:05 PM EDT - 2 months ago

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

Jul 28, 2025, 8:00 AM EDT - 2 months ago

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy

Jul 17, 2025, 8:00 AM EDT - 2 months ago

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025

Jul 14, 2025, 4:05 PM EDT - 2 months ago

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

Jun 18, 2025, 2:04 PM EDT - 3 months ago

Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

KIDZ LGHL VVPR

Jun 18, 2025, 8:32 AM EDT - 3 months ago

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

Jun 17, 2025, 3:54 PM EDT - 3 months ago

Eyenovia Surges on Crypto Announcement

Jun 17, 2025, 2:55 PM EDT - 3 months ago

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy

May 19, 2025, 5:30 PM EDT - 4 months ago

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Apr 10, 2025, 7:00 AM EDT - 6 months ago

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Feb 26, 2025, 7:00 AM EST - 7 months ago

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Feb 24, 2025, 7:00 AM EST - 7 months ago

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Feb 5, 2025, 7:00 AM EST - 8 months ago

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Jan 28, 2025, 4:05 PM EST - 8 months ago

Eyenovia Announces 1-for-80 Reverse Stock Split

Jan 15, 2025, 7:00 AM EST - 9 months ago

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Jan 6, 2025, 7:00 AM EST - 9 months ago

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Dec 6, 2024, 8:00 AM EST - 10 months ago

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Nov 22, 2024, 7:00 AM EST - 11 months ago

Eyenovia Provides Update on Restructuring Efforts

Nov 15, 2024, 1:15 PM EST - 11 months ago

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Nov 15, 2024, 7:07 AM EST - 11 months ago

Eyenovia to discontinue late-stage study for eye drug

Nov 15, 2024, 7:00 AM EST - 11 months ago

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Nov 12, 2024, 10:42 PM EST - 11 months ago

Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 11 months ago

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

Sep 27, 2024, 8:30 AM EDT - 1 year ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

Sep 9, 2024, 3:00 AM EDT - 1 year ago

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Aug 23, 2024, 11:42 AM EDT - 1 year ago

Eyenovia Announces Closing of Public Offering

Aug 22, 2024, 2:20 PM EDT - 1 year ago

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Aug 21, 2024, 9:29 AM EDT - 1 year ago

Eyenovia Announces Pricing of $5.14 Million Public Offering

Aug 20, 2024, 5:09 PM EDT - 1 year ago

Eyenovia, Inc. Announces Proposed Public Offering

Aug 12, 2024, 11:07 PM EDT - 1 year ago

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Aug 7, 2024, 5:11 PM EDT - 1 year ago

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Jul 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

NBY

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Eyenovia Announces Pricing of $5M Registered Direct Offering

Vikingsstrade Oct. 4 at 6:02 PM

0 · Reply

Jwa68 Oct. 4 at 2:32 PM

0 · Reply

SpencerF Oct. 3 at 7:52 PM

$HYPD think we just missed the last chance to dump? Or still Possibility of one more rally ahead?

0 · Reply

Vikingsstrade Oct. 3 at 4:29 PM

0 · Reply

LoneBroker Oct. 3 at 8:26 AM

0 · Reply

SpencerF Oct. 2 at 10:56 PM

$HYPD good to dump here? Have to do double bottom still?

0 · Reply

SmartBetting Oct. 2 at 8:04 PM

$HYPD i said. goodluck.

0 · Reply

StardustNdreams Oct. 2 at 7:09 PM

$HYPD excellent so far today

0 · Reply

S2K_TP Oct. 2 at 4:38 PM

$HYPD swing idea. Pt: 20+ 🚨🎢

0 · Reply

Drewcifer99 Oct. 2 at 1:33 PM

$HYPD hope the coin goes nuts soon. Would love to see this at $20 to $30!

0 · Reply

YorkMeister Oct. 2 at 12:17 PM

$HYPD 1,712,195 HYPx held at $50 = 86m MC 57m. Undervalued on hypx asset held by 30m, not taking into account eyenovia assets (about 10m) and revenue stream

1 · Reply

dogenationdog Oct. 2 at 4:56 AM

$HYPD 119.81%,short fee, 26.44% short float $HYPE.X on a rip higher watch out short squeeze !

0 · Reply

Jwa68 Oct. 2 at 12:35 AM

$HYPD Had the pleasure of speaking with new CFO David Knox today. I alwaya like to know the real person behind the executive title since management is always a company's most important asset. I found him highly knowledgeable, well spoken and genuinely likeable. Most importantly he strikes me as a man with a lot integrity who will place shareholders best interest first. A great complement to new CEO Hyunsu Jung.

0 · Reply

Jackie_Treehorn Oct. 1 at 4:11 PM

$SONN $HYPE.X $HYPD

0 · Reply

Doozio Oct. 1 at 3:57 PM

Da 🐑 ain’t $HYPD yet. But they will be unless a faatch 💣 lands during 🐒🍌🧠⏰♾️

0 · Reply

URANIO_ARRICCHITO Sep. 30 at 9:49 AM

$HYPD ... not so impressive... he was 'Head', not Director or Csomething... middle management

2 · Reply

Diiiii Sep. 30 at 3:07 AM

$HYPD A man with such an impressive resume chose to take the CFO position at this small company. This seems like a really surprising move.

0 · Reply

LoneBroker Sep. 29 at 8:59 PM

$HYPD • $10.24 🙂 • RSI 53.67 • ATR 15.75% • vol↓ Support & Resistance — UPDATED 09/29/2025 5 Days | Support: $8.00 – $10.10 | Resistance: $9.38 – $11.88 20 Days | Support: $5.54 – $11.75 | Resistance: $6.08 – $15.00 60 Days | Support: $5.08 – $13.61 | Resistance: $5.85 – $16.12 HYPD hovers in neutral territory with RSI near 53.67. ATR at 15.75% shows moderate activity. A move over $9.38 would signal strength, while slipping below $8.00 could pressure the tape. 🌐 Sentiment gauges flash neutral across sectors. Breakouts may run quickly if resting orders are cleared; reversals can be sharp. 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 🙂 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 4:00 PM ET / 1:00 PM PT (Mon–Fri)

0 · Reply

Drewcifer99 Sep. 29 at 5:15 PM

$HYPD come on Cathie ...buy some hypeiquid coins or this stock....either will work.

0 · Reply

Mike827 Sep. 29 at 3:51 PM

$HYPD we go from garbage scamming low level management to high level experts who are the best in the world 😂🤣🍾

0 · Reply

JBio Sep. 29 at 1:53 PM

$BNC Got in big. Obviously undervalued. It happened with $HYPD as well - was valued much below the worth of cash + coins. Easy x2 on your money.

0 · Reply

BuyOnRedSellOnGreen Sep. 29 at 1:17 PM

$HYPD impressive resume on this CFO hire

0 · Reply

Market Cap	82.33M
Revenue (ttm)	60,000.00
Net Income (ttm)	-49.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-83,033.33%
Debt to Equity Ratio	-0.96

Volume	700,800
Avg Vol	821,952
Day's Range	N/A - N/A
Shares Out	6.96M
Stochastic %K	79%
Beta	2.57
Analysts	Strong Buy
Price Target	N/A